BioNTech Target of Unusually Large Options Trading (NASDAQ:BNTX)

BioNTech SE (NASDAQ:BNTX) was the target of some unusual options trading on Monday. Stock traders purchased 1,989 call options on the company. This represents an increase of 31% compared to the average daily volume of 1,519 call options.

BioNTech Stock Performance

NASDAQ BNTX opened at $93.35 on Tuesday. The firm has a market capitalization of $22.19 billion, a P/E ratio of 22.66 and a beta of 0.25. The stock has a 50-day simple moving average of $90.54 and a two-hundred day simple moving average of $95.99. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.26 and a current ratio of 9.43. BioNTech has a fifty-two week low of $85.21 and a fifty-two week high of $125.83.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Wednesday, March 20th. The company reported $2.05 EPS for the quarter, missing the consensus estimate of $2.64 by ($0.59). The firm had revenue of $1.59 billion for the quarter, compared to analyst estimates of $2.04 billion. BioNTech had a net margin of 24.26% and a return on equity of 4.60%. On average, equities analysts forecast that BioNTech will post -1.74 earnings per share for the current year.

Institutional Trading of BioNTech

Institutional investors and hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC boosted its holdings in shares of BioNTech by 121.0% during the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after purchasing an additional 150 shares during the last quarter. CWM LLC grew its holdings in shares of BioNTech by 657.6% in the fourth quarter. CWM LLC now owns 250 shares of the company’s stock valued at $26,000 after purchasing an additional 217 shares during the period. Frazier Financial Advisors LLC acquired a new position in BioNTech in the 4th quarter valued at about $30,000. Covestor Ltd acquired a new stake in shares of BioNTech during the 3rd quarter worth approximately $32,000. Finally, First Horizon Advisors Inc. acquired a new position in BioNTech in the fourth quarter valued at approximately $38,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on BNTX. UBS Group dropped their price objective on shares of BioNTech from $110.00 to $101.00 and set a “neutral” rating for the company in a report on Wednesday, March 27th. HC Wainwright reaffirmed a “buy” rating and set a $107.00 price objective on shares of BioNTech in a report on Wednesday, April 17th. BMO Capital Markets cut their target price on shares of BioNTech from $127.00 to $123.00 and set an “outperform” rating for the company in a report on Thursday, March 21st. JPMorgan Chase & Co. decreased their price target on shares of BioNTech from $99.00 to $90.00 and set an “underweight” rating on the stock in a research note on Friday, March 22nd. Finally, The Goldman Sachs Group dropped their price objective on shares of BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a research note on Wednesday, February 28th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $120.40.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.